ARS Pharmaceuticals & CVS Health
2 shared events · Importance 3 · Last updated Sep 22, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
ARS Pharmaceuticals: ARS Pharmaceuticals is the defendant in the securities class actions and the central subject of the event. The litigation and the underlying neffy coverage setback weigh on its stock, financing options, and reputation.
CVS Health: CVS Health's decision to reserve expanded coverage of neffy until January 2027 triggered the stock drop that underpins the lawsuits. It faces no direct legal exposure in this matter.
Aug 06, 2026 · 174 articles
Regulatory
ARS Pharmaceuticals: ARS Pharmaceuticals is under investigation for potential violations of federal securities laws due to allegedly misleading statements regarding Neffy's commercial coverage, which led to a significant stock price drop.
CVS Health: CVS Health was specifically mentioned by ARS Pharmaceuticals' management as a key formulary addition expected by July 1, 2026, which did not materialize, contributing to the investigation.
Jun 26, 2026 · 6 articles
90
CVS Health reserved coverage decision ARS PharmaceuticalsARS Pharmaceuticals neffy...
80
ARS Pharmaceuticals announced no expanded coverage CVS HealthARS Pharmaceuticals neffy...
80
ARS Pharmaceuticals announced no expanded coverage CVS HealthARS Pharmaceuticals neffy...
80
CVS Health reserved coverage decision ARS PharmaceuticalsARS Pharmaceuticals neffy...
50
ARS Pharmaceuticals submitted formulary proposal CVS HealthARS Pharmaceuticals neffy...
ERGEN INTELLIGENCE
Explore this relationship live
Track how ARS Pharmaceuticals and CVS Health interact across events, view sentiment trends, and discover connected entities.
Open Dashboard